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SUMMARY
What is known and objective: Obesity is a signiﬁcant burden on
the healthcare system in the United States, and determining the
appropriate antimicrobial dosing regimen in morbidly obese
patients is challenging. Morbidly obese patients have docu-
mented differences in pharmacokinetic and pharmacodynamic
properties compared to normal-weight patients, which impact
antibiotic efﬁcacy and toxicity. The Food and Drug Administra-
tion does not recognize obesity as a special population and does
not require pharmaceutical companies to perform studies spe-
ciﬁc to obese patients. However, there are an increasing number
of post-approval studies in obese patients, and this manuscript
reviews available clinical and pharmacokinetic literature regard-
ing weight-based antimicrobial agents. Additionally, we
describe a single-centre approach to optimize dosing in mor-
bidly obese patients.
Methods: A comprehensive literature search was performed on
15 weight-based antimicrobials in the setting of obesity: acyclo-
vir, aminoglycosides, amphotericin B, cidofovir, colistimethate,
daptomycin, ﬂucytosine, foscarnet, ganciclovir, quinupristin/
dalfopristin, trimethoprim/sulfamethoxazole, vancomycin and
voriconazole. A weight-based antimicrobial dosing guideline for
morbidly obese patients was developed. An analysis of guide-
line compliance and cost analysis were performed following
guideline implementation.
Results and discussion: This review describes the pharmacoki-
netic changes that occur in obese patients, including increased
volume of distribution, altered hepatic metabolism, renal excre-
tion and changes in protein binding. The majority of weight-
based antimicrobials result in increased serum concentrations in
morbidly obese patients compared to normal-weight patients
when the calculated dose is based on actual body weight.
What is new and conclusion: This review demonstrates different
antibiotic pharmacokinetic properties are altered in obese
patients that could impact efﬁcacy and toxicity. A single-centre
guideline for weight-based antimicrobial dosing in obesity was
developed and provides recommendations for using ideal body
weight, adjusted body weight or actual body weight when
calculating antimicrobial doses. However, more research is
needed to better elucidate optimal dosing of weight-based
antimicrobials in obesity, with particular focus on efﬁcacy and
toxicity.
WHAT IS KNOWN AND OBJECTIVE
Obesity is a major issue in the United States, with 78 million US
adults and 125 million children and adolescents classiﬁed as
obese [body mass index (BMI) greater than or equal to 30].1 This
equates to an obesity rate of 35% and 169% in adults and children
in the United States, respectively.1 Physiological changes in obesity
can alter immunological pathways and increase the risk of central
line infection, post-operative surgical site infections, intensive care
unit length of stay and risk for severe pneumonia and inﬂuenza.2–5
Additionally, changes in antimicrobial pharmacokinetic and
pharmacodynamic properties are well documented, which impact
clinical success and risk of toxicity.2–5 Despite the unique charac-
teristics of the obese patient population, the Food and Drug
Administration does not require pharmaceutical manufacturers to
evaluate dosing recommendations in obesity. Calculating a
weight-based antibiotic regimen is particularly concerning, as
most antimicrobials do not signiﬁcantly penetrate adipose tissue
which results in increased serum concentrations in morbidly obese
patients.2–5 Some studies recommend using ideal body weight
(IBW) or adjusted body weight (AdjBW) when calculating an
antimicrobial dose in morbidly obese patients to strike a balance
between obtaining adequate serum antibiotic concentration to
effectively treat an infection while attempting to minimize
potential toxicities (Table 1).2–6 Weight-based antimicrobials in
this review include acyclovir, aminoglycosides, amphotericin B,
cidofovir, colistimethate, daptomycin, ﬂucytosine, foscarnet, ganci-
clovir, quinupristin/dalfopristin, trimethoprim/sulfamethoxazole,
vancomycin and voriconazole. General dosing recommendations
in obesity are provided for each agent reviewed; however, the
clinician must balance toxicity with efﬁcacy on a case-by-case basis
to avoid treatment failure and promotion of antimicrobial resis-
tance. Evaluation of compliance rates and cost savings are
analysed following implementation of weight-based antimicrobial
dosing recommendations in morbidly obese patients at the
University of Michigan Hospitals and Health System (UMHS).
PHARMACOKINETIC ALTERATIONS IN OBESITY
Differences in proportion of adipose tissue, lean muscle tissue and
ﬂuid status can greatly affect pharmacokinetic differences between
patients, and absorption, distribution, metabolism and excretion
are altered in obese patients (Table 2). Modest changes in oral
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absorption can occur in obesity secondary to delays in gastric
emptying, likely caused by differences in dietary habits compared
to non-obese subjects.6 Drug absorption is also delayed or
incomplete following subcutaneous injections in morbid obesity.
Intramuscular injections may also inadvertently be given as a deep
subcutaneous injection due to increased quantity of adipose
tissue.6
The volume of distribution (Vd) in obesity can be dramatically
different compared to normal-weight patients.2,4,5 The extent of
change of drug distribution is primarily based on its intrinsic
characteristics such as molecular size, degree of ionization, extent
of lipid solubility, protein binding and ability to cross biological
membranes.7 Obesity does not signiﬁcantly alter albumin binding
of medications but may have alterations in lipoproteins and
alpha1-acid glycoprotein although studies are inconclusive.8,9
Other physiological changes, such as tissue blood ﬂow and
changes in cardiac output, can also alter drug distribution,
although the signiﬁcance of these changes is yet to be deter-
mined.6,7
Physiological changes in the liver and kidneys of obese patients
can alter metabolism and excretion.2,4 The increased presence of
fatty inﬁltration in the liver can alter blood ﬂow and thus drug
metabolism.6,7 Additionally, level of cytochrome P450 pathway
activity might be altered in obese patients. One study demon-
strated increased activity of CYP2E1 and reduced CYP3A4 in
obesity, with trends towards change with other CYP isozymes.9
Obesity can increase glomerular ﬁltration rate (GFR), but this
observation is primarily associated with otherwise healthy
patients.2 Obesity in the presence of other comorbidities, especially
hypertension, can increase the risk for chronic renal dysfunction.2
A study conducted in healthy obese patients utilizing common
equations for evaluating creatinine clearance or estimated GFR
showed both overestimation and underestimation when compared
to measured GFR, which can impact the dose and frequency of
antimicrobials.10 Similarly, obese patients in intensive care units
may have larger ﬂuctuations in beta-lactam serum concentra-
tions.11
REVIEW OF ANTIMICROBIAL AGENTS
Aminoglycosides
Pharmacokinetics of amikacin, gentamicin and tobramycin in
obesity are well documented and described in at least 11 human
studies (Table 3). Most studies demonstrate a need for dose
adjustments in obesity and recommend use of AdjBW. The
recommended correction factor varied slightly among studies,
which is likely the result of different patient populations and
dosing regimens.2,12–21 Nine studies recommend AdjBW with
adjustments ranging from 020 to 058 [IBW plus 20–58% difference
between actual body weight (ABW) and IBW].2,12,13,15–18,20,21 Only
one study did not ﬁnd a difference in pharmacokinetics between
obese and normal-weight patients.19 This study examined genta-
micin and tobramycin in 27 obese peri-partum women and was
underpowered to demonstrate statistical signiﬁcance.
The available literature evaluating aminoglycoside dosing in
obesity often has small sample sizes, includes single-dose phar-
macokinetic studies and rarely assesses safety. However, the
results largely support the use of AdjBW when dosing aminogly-
cosides in obesity, often with a weight of IBW plus approximately
40% of the excess body weight. Additionally, obesity recommen-
dations are provided in the tobramycin prescribing information,
which recommends use of AdjBW [lean body weight (LBW) plus
40% of the excess body weight] when calculating a dosing
regimen.22
Colistimethate
Colistimethate studies in obesity are described in three retrospec-
tive studies, one prospective study and one case report.23–27 A
prospective study by Garonzik et al.26 examined pharmacokinetics
of colistimethate in approximately 100 patients with doses ranging
from 75 to 410 mg daily. A linear pharmacokinetic model was
Table 1. Equations used to calculate body mass index (BMI), lean
body weight (LBW), ideal body weight (IBW) and adjusted body
weight (AdjBW)
Measure Formula
BMI (kg/m2) BMI = ABW/(height in metres)2
IBW kg) Males: IBW = 50 + 23 (height in inches  60 inches)
Females: IBW = 455 + 23 (height in inches  60 inches)
LBW (kg) Males: LBW = [9270 9 ABW]/[6680 + (216 9 BMI)]
Females: LBW = [9270 9 ABW]/[8780 + (244 9 BMI)]
AdjBW (kg) AdjBW = IBW + [(ABW  IBW) 9 correction factor]
ABW, actual body weight.
Table 2. Physiological and pharmacokinetic factors altered in
obese patients
Parameter Changes in obesity
Absorption Changes in gastric motility can alter oral absorption
Changes in body composition
• Subcutaneous absorption delayed or incomplete
with increased adipose tissue
• Intramuscular injections mistakenly given as
deep subcutaneous injections
Distribution Little/no change in volume of distribution expected if
• Large molecular size
• Highly ionized
• Highly protein bound
• Poorly crosses biological membranes
Increase in volume of distribution expected if
• Small molecular size
• Minimally ionized
• Minimally protein bound
• Easily crosses biological membranes
Metabolism Increased fatty inﬁltration of liver
• Altered blood ﬂow and metabolismChange
in activity level of cytochrome P450 enzymes
Elimination Variable effects on kidney function
• Increased glomerular ﬁltration rate in healthy
obese patients
• Possible kidney dysfunction with comorbid
conditions
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developed using serum colistin methanesulfonate concentrations
and suggested only the loading dose should be weight based.
Nearly half of the patients had an increase in serum creatinine of
over 50% from baseline, although the impact of weight was not
examined on this safety measure.25
Pogue et al.23 assessed the incidence of and risk factors for
colistimethate-associated nephrotoxicity in a large academic
health system in 126 patients. Nephrotoxicity developed in 43%
of patients and was associated with a higher mg/kg/day dose of
colistimethate (relative to IBW). A statistically signiﬁcant trend
also existed between increasing overall dose and frequency of
nephrotoxicity. These results weaken the argument to utilize
ABW in dosing. A similar retrospective cohort study by Deryke
et al.24 in 30 patients found excessive colistimethate dosing was
associated with higher rates of nephrotoxicity (80% vs. 30%,
P = 0019).
Gauthier et al.25 examined colistimethate in 42 overweight and
obese individuals through a retrospective case-controlled study
using doses based on prescribing information recommendations.
Nearly half of the patients developed nephrotoxicity within a
median of 5 days. A BMI of >31 kg/m2, age, diabetes and length
of stay prior to colistimethate initiation were all independent risk
factors for nephrotoxicity.
In summary, there are limited data comparing pharmacokinet-
ics of colistimethate in obese vs. normal-weight patients. However,
multiple studies demonstrate signiﬁcant risk of nephrotoxicity
with colistimethate in obese patients, and dosing based on IBW or
AdjBW may be prudent, with infection severity driving the
decision on a case-by-case basis.
Daptomycin
Daptomycin use in obese patients is assessed in six separate
human trials and one case report. The drug is a large molecule
(1620 Da), highly protein bound (90–95%), and has a fairly small
Vd (01 L/kg) in healthy volunteers.28 The prescribing information
reports the plasma clearance of daptomycin as 15–23% lower in
obese patients based on data from 12 obese or extremely obese
patients, which is attributed to decreased renal function as
opposed to obesity itself.
Pai et al.29 performed a 4 mg/kg (based on ABW) single-dose
pharmacokinetic study in 14 adult female morbidly obese and
non-obese patients. The morbidly obese group yielded a 60%
increase in Cmax (673 vs. 423 mg/L, P = 0029) and 60% increase
in AUC (494 vs. 307 mg h/L, P = 0002) compared to the non-
obese group. The relationship of Vd and total clearance with
weight was best predicted by ABW (r2 = 066 and 03, respec-
tively) and BMI (r2 = 052 and 024, respectively) when evaluated
with linear regression.
Dvorchik et al.30 also performed a single-dose pharmacokinetic
evaluation of daptomycin in 25 obese and non-obese patients
receiving 4 mg/kg based on ABW. Cmax and AUC0–∞ increased by
25% and 30%, respectively, in morbidly obese compared to non-
obese patients [average Cmax of 67 vs. 53 lg/mL (P = 0030),
average AUC0–∞ of 548 vs. 419 lg h/mL (P = 0004)]. Absolute Vd
increased 55% in morbidly obese relative to non-obese patients.
Bubalo et al.31 examined the pharmacokinetics of daptomycin in
29 oncology patients with neutropenic fever. BMI ranged from 19
to 46 kg/m2, and daptomycin was dosed at 6 mg/kg ABW.
Average daptomycin clearance decreased as BMI increased:
1893  724 mL/h/kg in normal-weight subjects, 1465 
308 mL/h/kg in overweight subjects, 1186  516 mL/h/kg in
obese subjects and 1141  429 mL/h/kg in morbidly obese
subjects. This corresponds to an approximate 60% reduction in
total body clearance in obese or morbidly obese patients relative to
healthy subjects. A post hoc analysis showed a signiﬁcant difference
in clearance between normal-weight and obese subjects
(P = 0015). No other pharmacokinetic parameters differed signif-
icantly by BMI. No patients experienced myopathy or required
daptomycin to be discontinued due to elevated creatine phospho-
kinase (CPK) levels. The authors conclude a 6 mg/kg ABW dose
every 24 h was both effective and well tolerated in adult oncology
patients.
A case report was also published describing a 63-year-old
severely obese male (BMI 816 kg/m2) treated with daptomycin,
with dosing dictated by therapeutic drug monitoring.32 The Vd
was anticipated to be approximately 009 L/kg based on previous
literature in obese patients, but the patient’s Vd was 008 L/kg,
with a Cmax of 5748 mg/L after a 1200 mg dose (48 mg/kg
ABW). CPK increased more than three times the baseline value by
day 3 but normalized by day 7. In this case, the use of an adjusted
dose resulted in reaching pharmacokinetic goals in an obese
patient.
Two studies have demonstrated an increased risk of daptomy-
cin myotoxicity in obese patients.33,34 A post hoc analysis following
a phase 3 trial evaluating daptomycin vs. vancomycin in patients
with Staphylococcus aureus bacteremia was performed by Bhavnani
et al.,33 and they examined the incidence and risk factors for
adverse events (i.e. elevations in CPK) in 108 patients receiving
6 mg/kg ABW every 24 h. They found CPK elevations in
approximately 6% of patients, and risk factors for toxicity were
obesity (ABW >110 kg) and daptomycin trough concentration
>243 mg/L. A multicentre retrospective cohort study by Bookst-
aver et al.34 included 126 obese patients dosed by ABW for any
indication and found CPK elevations of more than 1000 units/L in
84% of patients and elevations of more than 500 units/L in nearly
14% of patients. Discontinuation of therapy due to adverse effects
of daptomycin occurred in 63% of patients, and the authors
concluded there were increased CPK elevations in obesity with
overall low rates of drug discontinuation.
Finally, Ng et al.35 examined clinical efﬁcacy of daptomycin
dosing based on IBW vs. ABW, following an institutional
guideline recommending daptomycin dosing based on IBW. They
examined 107 patients treated with daptomycin 4–6 mg/kg with
Enterococcus or Staphylococcus infection, with the primary outcome
of clinical success (resolution of signs and symptoms of infection
and/or no additional gram positive coverage from other antibi-
otics), or clinical improvement. No statistically signiﬁcant differ-
ences were found between overall clinical and microbiological
cure. No signiﬁcant differences were seen in the number of adverse
events in either dosing group; however, CPK levels were only
available in 33% of the patients. Nonetheless, prescribing bias was
likely present towards less severe infections within the IBW group,
as more patients were treated for urinary tract infections.
In summary, there are prospective pharmacokinetic studies
recommending the use of ABW, a retrospective study advocating
the use of IBW, and a case report that promotes the use of AdjBW
when dosing daptomycin in obese patients. Therefore, daptomycin
dosing in obese patients based on IBW or AdjBW appears to have
similar pharmacokinetics as normal-weight patients, similar efﬁ-
cacy, lower cost and lower risk of adverse effects. Although the
rate of CPK elevation is relatively low, utilizing ABW in obese
patients is a risk factor for toxicity. More studies are needed that
focus on clinical efﬁcacy and toxicity, and dosing should be
© 2014 John Wiley & Sons Ltd Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 584–608
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determined in the context of infection severity and include close
monitoring.
Quinupristin/dalfopristin
Quinupristin/dalfopristin pharmacokinetics in obesity have been
examined in one single-dose pharmacokinetics study. In normal
healthy patients, the Vd for quinupristin is 045 L/kg and for
dalfopristin is 024 L/kg.36 Quinupristin has a molecular weight of
1022 Da while dalfopristin is 690 Da, and the per cent protein
bound is higher for quinupristin than dalfopristin, although the
general percentage is not reported in the package insert. Both
compounds are primarily excreted in the faeces, likely through
excretion in the bile. Despite the lack of data in obese patients, the
prescribing information notes an increase in both Cmax and AUC
by 30–40% in patients with a BMI ≥30 kg/m2, although no dose
adjustments are suggested. A small study performed in 1997 found
that both Cmax and AUC increased by 25% in obese patients
(BMI > 30 kg/m2) relative to non-obese patients after 75 mg/kg
of quinupristin/dalfopristin based on ABW.37 Decisions regarding
the appropriate weight to use for dosing should be made on a case-
by-case basis while balancing risk vs. beneﬁt and taking into
consideration disease severity.
Sulfamethoxazole/trimethoprim
Sulfamethoxazole/trimethoprim pharmacokinetics in obesity have
not been examined in human studies; however, one small human
study in a related sulphonamide antibiotic, sulﬁsoxazole, has been
performed. Sulfamethoxazole/trimethoprim is lipophilic, highly
protein bound (70% for sulfamethoxazole, 44% for trimethoprim)
and excreted primarily through the kidneys.38 Both components
are similarly small at 253 and 290 Da for sulfamethoxazole and
trimethoprim, respectively.
A small study performed by Garrett et al.39 examined pharma-
cokinetic properties of 1 g of IV sulﬁsoxazole, another sulphona-
mide antibiotic with similar pharmacokinetic properties to
sulfamethoxazole, in four morbidly obese patients after jejunal–
ileal bypass surgery. Pharmacokinetic parameters were collected
after a single dose prescribed at 1 week presurgery and 1 week,
6 weeks, 6 months, and 12 months after surgery, and renal
function remained stable throughout the study. Although up to
44% of body weight was lost after the ﬁrst year, Vd did not change,
suggesting an obese individual may require a dose similar to a
normal-sized individual – for weight-based dosing, this would
involve using an AdjBW. Safety was not assessed.
Ultimately, without clinical data to support a speciﬁc dosing
strategy, decisions regarding the appropriate weight to use for
dosing should be made on a case-by-case basis. Monitoring for
signs of clinical improvement and drug toxicity is crucial.
Vancomycin
Vancomycin pharmacokinetics in obesity are extensively examined
in the literature. The drug is primarily eliminated via the kidneys,
55% bound to serum proteins, and Vd ranges from 03 to 043 L/kg
in normal-weight patients.40 The prescribing information for
vancomycin does not address its use in obese patients.
A retrospective matched study by Bauer et al.41 examined
vancomycin pharmacokinetics in 48 morbidly obese and non-
obese patients. When normalized by ABW, clearance and Vd did
not differ between groups, but a reduced half-life was observed
in the obese group. A study by Vance-Bryan et al.42 assessed
vancomycin concentrations in 230 patients stratiﬁed by body
weight. ABW was a signiﬁcant predictor for both Vd, and
multiple regression models showed ABW was superior to LBW
when determining initial dosing requirements. Safety was not
assessed in any of these retrospective studies. Finally, a case
report by Penzak et al.43 detailing a morbidly obese male with
methicillin-resistant S. aureus foot ulcers treated with vancomy-
cin showed ABW as opposed to IBW was more accurate in
predicting the best dose for the patient in three of four dosing
nomograms.
Blouin et al. published a prospective trial examining vancomy-
cin dosing in obesity. In an uncontrolled, multiple-dose pharma-
cokinetic study, four non-obese patients were compared to six
morbidly obese patients who received a single dose of vancomycin
after gastric bypass.44 Authors observed a strong positive corre-
lation between ABW and both Vd and clearance of vancomycin
(correlation coefﬁcient of 094 and 098, respectively). No signif-
icant difference in mg/kg daily dose required to reach the goal
drug serum concentration of 15 lg/mL was noted between
groups. These data support the use of ABW when dosing
vancomycin in obese patients.
Another large retrospective study including 700 patients by
Ducharme et al.45 looked at the pharmacokinetics of vancomycin.
Vd adjusted for IBW was found to be greater in obese patients than
in normal patients, and the authors noted that female gender, older
age and obesity all resulted in higher Vd through the use of
regression equations. They recommend adjusting dose based on
these factors. Another study by Leong et al. compared vancomycin
clearance in overweight and obese patients to determine the best
body weight measurement to use when dosing. However, only
vancomycin troughs were available for assessment, and therefore,
differences in Vd were not able to be assessed.
46 The authors
concluded AdjBW was the best predictor of vancomycin clearance
and serum concentrations. Finally, a study by Reynolds et al.47
compared doses and serum drug concentrations before and after a
change in the institution’s vancomycin dosing protocol. The
protocol was changed from 15 mg/kg every 8–12 h to either
10 mg/kg every 12 h or 15 mg/kg every 24 h in obese patients.
This resulted in a lower adjusted maintenance dose for obese
patients of 19 mg/kg/day in the new protocol as opposed to
34 mg/kg/day in the prior protocol. The authors found an
increase in frequency of target trough attainment and below-
target attainment and a reduced frequency of supratherapeutic
troughs. The revised protocol with lower total daily doses
improved target trough attainment with minimal nephrotoxicity
(12%) utilizing ABW.
Vancomycin clearance and Vd have been shown to increase in
obese patients, which correspond with the need for increased
doses in larger patients. However, a retrospective study by Heble
et al.48 in a group of obese and non-obese paediatric patients
showed obesity to be an independent risk factor for elevated
steady-state troughs when receiving equivalent doses by ABW.
Presently, studies utilizing AdjBW provide insufﬁcient data to
support its use, although they have shown a correlation between
AdjBW and Cockroft–Gault-predicted creatinine clearance,
which can correlate to drug clearance. Overall, dosing vancomy-
cin based on ABW is likely appropriate for initial dosing
recommendations followed by therapeutic drug concentration
monitoring, but obese patients may have reduced clearance and
therapeutic drug monitoring of vancomycin trough levels is
encouraged.
© 2014 John Wiley & Sons Ltd Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 584–608
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REVIEW OF ANTIFUNGAL AGENTS
Amphotericin B
Amphotericin B pharmacokinetics in obesity has been evaluated in
four animal studies, but there is currently no published literature
in humans (Table 4). Amphotericin B has nonlinear kinetics,
resulting in a large increase in serum levels compared to the
magnitude of increase in dose.49 The Vd for liposomal amphoter-
icin B is relatively small and ranges from 01 to 016 L/kg in
hemopoetic stem cell transplant recipients and patients with
cancer, which suggest limited drug distribution into adipose
tissue.
Vadieie et al.50 studied amphotericin B disposition in the
hyperlipidemic Zucker rat compared to lean littermates. Serial
blood samples were obtained after a single 12 mg/kg dose and
showed a twofold increase in AUC in obese rats. Weight-corrected
Vd and total body clearance were signiﬁcantly lower in the obese
rats. There was a signiﬁcant decline in creatinine clearance from
baseline in obese rats, whereas lean rats showed no difference in
renal function.
Another study performed in non-infected rabbits by Groll
et al.51 examined amphotericin B concentrations in various body
tissues after administration of different drug formulations, includ-
ing amphotericin B deoxycholate, amphotericin B colloidal dis-
persion, amphotericin B lipid complex or liposomal amphotericin
B. Compared to bone marrow and the liver, accumulation in fat
tissue was relatively poor with concentrations being 22% or less
than that found in liver or bone marrow for all formulations tested.
Authors suggest dosing obese patients based on LBW accounting
for expanded blood volume.
Two additional studies examined amphotericin B in hypercho-
lesterolaemic rabbits.52,53 Ramaswamy et al. found that AUC was
signiﬁcantly higher and steady-state Vd was signiﬁcantly lower in
cholesterol-fed rabbits relative to regular diet-fed rabbits. Signif-
icant increases in plasma creatinine levels were also observed in
both diet groups. Koldin et al. saw no difference in rabbit survival
rates or elevations of creatinine levels between groups when
comparing normal and hypercholesterolaemic rabbits. Rabbits in
both studies had similar ABW between groups but differences in
serum cholesterol levels.
Prescribing information recommends weight-based doses rang-
ing from 3 to 6 mg/kg/day depending on indication for liposomal
and lipid-based products, but no recommended maximum dose is
suggested and use in obesity is not addressed.49 Animal studies
demonstrate signiﬁcant increase in amphotericin B serum concen-
tration in obese rats and rabbits with poor lipid distribution and
increased rates of nephrotoxicity. Use of IBW or AdjBW could be
considered when determining doses for morbidly obese patients
depending on the indication for use. More aggressive dosing could
be warranted in certain situations, and the limitations of utilizing
animal data for human dosing recommendations should be
acknowledged.
Flucytosine
Flucytosine pharmacokinetics in obesity have been described in
one case report.54 Flucytosine is small (129 Da), only 3–4%
protein bound and has a modest Vd of approximately 06 L/kg in
normal patients.49 A case report discusses a morbidly obese
female who received 03–05 mg/kg/day IBW for treatment of
extrameningeal cryptococcal infection with resolution of infection.
The patient had apparent CL of 15 and 071 mL/min/kg and Vd
of 083 and 04 L/kg relative to IBW and ABW, respectively. The
authors recommend use of IBW as opposed to ABW as the
examined pharmacokinetic parameters seemed to correlate best
with non-obese patients when standardized to IBW. The use of
ABW for ﬂucytosine dosing in obese patients in the absence of
robust clinical data may be prudent – given its Vd – for initial
dosing of life-threatening fungal infections, but therapeutic drug
monitoring and individualized dosing are highly recommended.
For non-life-threatening infections, doses based on IBW may be
sufﬁcient.
Voriconazole
Voriconazole pharmacokinetics in obesity have been examined in
one small randomized trial, two retrospective studies and three
case reports. The Vd for voriconazole is 46 L/kg and correlates
with high tissue distribution.55 The hepatic cytochrome P450
enzymes metabolize voriconazole and are the primary route of
elimination.55 Voriconazole metabolism is nonlinear, and serum
concentrations are signiﬁcantly increased following saturation of
cytochrome P450 enzymes. Additionally, per cent plasma protein
binding is 58%. The prescribing information recommends a
loading dose of 6 mg/kg/dose IV every 12 h followed by 4 mg/
kg/dose IV or 200 mg PO every 12 h, but dosing in obesity is not
speciﬁcally addressed.
In 2011, a randomized, crossover study was performed in 16
obese and non-obese patients (mean BMI 46 and 24 kg/m2,
respectively).56 Patients received either 400 mg of oral voriconaz-
ole every 12 h for two doses followed by 200 mg every 12 h for
seven doses or 400 mg every 12 h for two doses followed by
300 mg every 12 h for seven doses. The authors found the Vd and
clearance of the drug to be similar between weight groups;
however, AUC was 50% greater in obese patients. The study
suggests the use of LBW over ABW when dosing voriconazole in
obese patients.
Two retrospective studies conducted support the use of
AdjBW for dosing voriconazole. A retrospective review by
Koselke et al.57 compared voriconazole levels in obese and non-
obese patients when given 4 mg/kg ABW doses. A signiﬁcantly
higher voriconazole trough concentration was observed in obese
patients compared to non-obese patients (62 vs. 35 mg/L,
P > 00001). The authors also compared dosing strategies in all
obese patients who received dosing based on ABW, AdjBW and
IBW. Mean serum trough concentrations in obese patients were
27, 32 and 62 mg/L when dosed by IBW, AdjBW and ABW,
respectively (P < 00001). No obese patients dosed based on IBW
or AdjBW experienced supratherapeutic levels. Therapeutic
trough levels were achieved more often in patients dosed by
IBW or AdjBW (60% and 67%, respectively) compared to ABW
(28%). The authors concluded voriconazole should not be dosed
based on ABW.57 A retrospective chart review by Davies-
Vorbrodt et al.58 examined patients on voriconazole with
documented serum concentrations stratiﬁed by BMI. Random
voriconazole serum levels were signiﬁcantly higher in patients
with BMI of 25 kg/m2 or more compared to those with lower
BMI.58 The authors recommend use of AdjBW when dosing
voriconazole in obese patients.58 The use of AdjBW has also been
recommended in three different case studies, with two patients
poor voriconazole metabolizers.59–61
Although available literature includes retrospective studies
with small sample sizes, there is a strong association with
© 2014 John Wiley & Sons Ltd Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 584–608
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increased voriconazole concentrations in obese patients receiv-
ing ABW dosing. Empiric dosing based on AdjBW or IBW
should be considered; however, adjustments should be made
on a case-by-case basis depending on infection severity, and
early therapeutic drug concentration monitoring is recom-
mended.
REVIEW OF ANTIVIRAL AGENTS
Acyclovir
Acyclovir pharmacokinetics in obesity have not been evaluated in
animal studies, but there are two case reports and one small
human study (Table 5). Acyclovir is a small drug (225 Da) with
low plasma protein binding (9–33%). Half-life and total body
clearance are dependent on renal function, and acyclovir has a Vd
of approximately 48 L/m2.62,63
An abstract presented at the Interscience Conference on Anti-
microbial Agents and Chemotherapy in 1991 described a single-
dose pharmacokinetics study in obese and non-obese patients.64
The authors found that Vd in both groups was approximately 43 L,
leading them to conclude that IBW should be utilized when dosing
acyclovir in obesity.
Hernandez et al.65 describe a 60-year-old obese male (BMI
376 kg/m2) with suspected herpes encephalitis receiving acyclo-
vir at roughly 9 mg/kg/dose ABW IV every 8 h. By day 3, serum
creatinine and BUN signiﬁcantly increased, which prompted a
discontinuation of acyclovir. The patient was diagnosed with
acyclovir-induced nephrotoxicity and acute renal failure. Efﬁcacy
of treatment could not be assessed as herpes encephalitis was
ultimately ruled out and the patient was lost to follow-up. Another
case report involved a 23-year-old morbidly obese male with
suspected viral encephalitis given acyclovir 10 mg/kg/dose ABW
IV every 8 h.66 Within 48 h, renal function deteriorated and
acyclovir was discontinued.
Based on recommendations from the manufacturer’s prescribing
information, as well as these the limited literature, weight-based
treatment dosing of acyclovir should be based on IBW.67
Cidofovir
Cidofovir pharmacokinetics in obesity have not been evaluated in
animal studies, and no published literature in human patients
currently exists. The average Vd when given with probenecid is
041 L/kg, and <6% of the drug is bound to serum proteins.68 It is
a small drug at 315 Da. No recommendations for dosing in obesity
exist in the prescribing information, but pharmacokinetic values in
non-obese patients suggest limited distribution into adipose tissue.
As a result, decisions regarding the appropriate weight to use
when calculating cidofovir dose should be made on a case-by-case
basis while balancing risk vs. beneﬁt.
Foscarnet
Foscarnet pharmacokinetics in obesity have not been evaluated in
animal or human subjects. It is a small (300 Da), hydrophilic agent
and in non-obese adults has a Vd of 04–05 L/kg, protein binding
of 14–17% and is primarily eliminated via the kidney.69 Recom-
mendations are not provided in the prescribing information
regarding dosing in obese patients. Due to its hydrophilic nature,
major risk of nephrotoxicity and other adverse effects, it may be
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Ganciclovir
Ganciclovir pharmacokinetics in obesity have not been evaluated
in animal or human subjects. In non-obese adults, ganciclovir has a
steady-state Vd of 074 L/kg, and binding to plasma proteins is
minimal at 1–2%, which is similar to acyclovir.70 Dosing in obese
patients is not addressed in the prescribing information. Due to the
hydrophilic nature of ganciclovir and its similarity in size (277 Da),
action and toxicity to acyclovir, utilization of IBW when calculat-
ing doses in obese patients could be considered on a case-by-case
basis.
UMHS DOSING RECOMMENDATIONS AND COST
ANALYSIS
In the summer of 2012, UMHS implemented a weight-based
antimicrobial dosing guideline for select antimicrobials in mor-
bidly obese patients (Table 6). The recommendations were devel-
oped following extensive literature review and expert opinion for
the following antimicrobials: colistimethate, daptomycin, trimeth-
oprim/sulfamethoxazole, acyclovir, foscarnet, ganciclovir and
voriconazole. The Pharmacy and Therapeutics Committee
approved the guideline, which recommends using AdjBW for
patients with BMI ≥35 kg/m2 for daptomycin, trimethoprim/
sulfamethoxazole, foscarnet, ganciclovir, and voriconazole and
IBW when calculating the dose for acyclovir and colistimethate.
The recommendations were posted on the internal antimicrobial
stewardship website, and pharmacists were provided a copy of the
recommendations. Pharmacists were encouraged to recommend
dose adjustments for obese patients upon order veriﬁcation or
during daily patient rounds, but there were no prompts built into
our computerized physician order entry system during this
timeframe.
Compliance with dosing recommendations and cost analysis
were performed for all morbidly obese patients (BMI > 35 kg/m2)
receiving weight-based dosing of antimicrobials for a 1-year
period (November 2012 through November 2013). Compliance
with the guideline recommendations occurred in 64% of doses
dispensed, which resulted in an annual antimicrobial cost savings
of $97 886, based on average wholesale price (Table 7). If 100%
compliance with the guideline was attained, an additional savings
potential of $29 733 would be achieved. Efﬁcacy and safety were
not evaluated.
WHAT IS NEW AND CONCLUSION
Optimal antimicrobial dosing in obese patients continues to
present challenges. Most current publications are pharmacokinetic
studies with limited data evaluating clinical efﬁcacy and toxicity.
However, morbidly obese patients have altered pharmacokinetic
properties for most weight-based antimicrobials compared to
normal-weight patients. Providing adjusted-dose weight-based
antimicrobial dosing in morbidly obese patients may help maxi-
mize efﬁcacy, minimize toxicity and provide antimicrobial cost
savings. However, clinical judgment should always be used when
making dose adjustments in obese patients, particularly for agents
with scarce available literature in obese patients.
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